Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
Introduction Maraviroc inhibits CCR5-tropic HIV-1 across different subtypes in vitro and has demonstrated efficacy in clinical trials. V3-loop amino acid variants observed in individual maraviroc-resistant viruses have not been found to be predictive of reduced susceptibility. Sequence-database sear...
Main Authors: | ME Lewis, B Jubb, P Simpson, A Lopatukhin, D Kireev, M Bobkova, C Craig, E van der Ryst, M Westby, SL Butler |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-06-01
|
Series: | Antiviral Chemistry & Chemotherapy |
Online Access: | https://doi.org/10.1177/20402066211025156 |
Similar Items
-
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
by: ME Lewis, et al.
Published: (2021-07-01) -
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
by: Becky Jubb, et al.
Published: (2019-12-01) -
Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01) -
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
by: Marilyn Lewis, et al.
Published: (2018-01-01) -
Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)